Publications by authors named "Zeljko Obradovic"
Article Synopsis
- Adropin is a protein that plays a role in regulating metabolic functions related to heart failure (HF) and the heart-brain-kidney axis.
- A study investigated the relationship between serum adropin levels and chronic kidney disease (CKD) in type 2 diabetes patients with chronic HF, using 417 participants, including healthy controls.
- Findings indicated that lower adropin levels (below 2.3 ng/mL) in T2DM patients with chronic HF significantly predicted the presence of CKD, suggesting that adropin could be a useful biomarker for assessing kidney health in these patients.
Article Synopsis
- Adropin plays a key protective role in heart health, particularly by supporting energy metabolism and reducing inflammation, with low levels linked to cardiovascular issues and type 2 diabetes.
- A study involving 417 patients with type 2 diabetes and heart failure showed that treatment with the SGLT2 inhibitor dapagliflozin significantly increased adropin levels after six months, with more pronounced increases in females compared to males.
- Changes in heart function (like left ventricular ejection fraction) were found to be related to adropin level increases, suggesting that higher adropin levels could help predict improvements in heart performance during SGLT2 treatment.
Article Synopsis
- Cardiac hepatopathy is liver damage caused by heart dysfunction, often linked to poor outcomes in patients with heart failure.
- Current understanding fails to connect metabolic proteins from liver cells, known as hepatokines, with the progression of heart failure and related complications.
- This review aims to examine how these hepatokines may help maintain metabolic balance and protect against various forms of cellular damage in heart failure patients, highlighting the need for further research.
Hyperglycemia is a trigger for structural alteration of red blood cells (RBCs) and their ability to release extracellular vesicles (EVs). The aim of the study was to elucidate whether glucose control in T2DM patients with concomitant HF and AF affects a circulating number of RBC-derived EVs. We prospectively included 417 T2DM patients with HF, 51 of them had atrial fibrillation and 25 healthy volunteers and 30 T2DM non-HF individuals.
View Article and Find Full Text PDFType 2 diabetes mellitus (T2DM) remains a powerful predictor of progressive heart failure (HF), but it is not clear whether altered glycemic control interferes with HF progression via an impaired profile of circulating myokines. The aim was to investigate plausible effects of glucose control on a myokine signature in T2DM patients affected by chronic HF. We selected 372 T2DM patients from the local database and finally included 314 individuals suffering from chronic HF and subdivided them into two groups according to glycosylated hemoglobin (HbA1c) levels (<6.
View Article and Find Full Text PDF